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Oxycodone for Cancer Pain in Adult Patients
Mia Schmidt-Hansen, BSc, PhD; Michael I. Bennett, MB, ChB, MD, FRCP; Jennifer Hilgart, BSc, MSc
Many patients with cancer experiencemoderate or severe pain re-
quiring treatmentwith strong opioids. However, not all opioids are
well tolerated by all patients. This JAMAClinical Evidence Synopsis
summarizes a publishedCochrane review1 that examined the asso-
ciation of oxycodone (any formulation or route of administration)
comparedwithplacebooranactivedrug(includingalternative forms
of oxycodone) for treating cancer pain in adults.
Summary of Findings
Because the studies used different scales tomeasure pain intensity,
meta-analysis was performed using the standardized mean differ-
ence (SMD) to compare pain intensity across studies. Pain scores
were not significantly different between controlled-release (CR)
vs immediate-release (IR) oxycodone (SMD, 0.1 [95% CI, −0.06 to
0.26]) or between CR oxycodone vs CR morphine (SMD, 0.14
[95% CI, −0.04 to 0.32]; Figure). The most commonly reported
adverse events were constipation, drowsiness, and nausea in the
studies comparing CR and IR oxycodone (for constipation, 13.9%
for CR oxycodone [26/187 patients] vs 19.4% for IR oxycodone
[37/191 patients]; for drowsiness, 20.9% for CR oxycodone
[39/187 patients] vs 19.9% for IR oxycodone [38/191 patients];
and for nausea, 19.3% for CR oxycodone [36/187 patients] vs 22%
for IR oxycodone [42/191 patients] and in the studies comparing
CR oxycodone with CR morphine (for constipation, 28.1% for CR
oxycodone [50/178 patients] vs 30.6% for CR morphine [53/173
patients]; for drowsiness, 17.2% for CR oxycodone [26/151 patients]
vs 23.3% for CR morphine [34/146 patients]; and for nausea,
17.4% for CR oxycodone [31/178 patients] vs 22% for CR morphine
[38/173 patients]). There were no or only minor differences in
adverse event rates, treatment acceptability or quality-of-life
ratings in studies comparing CR oxycodone with either IR oxyco-
done or CR morphine. The remaining studies reported different
drug comparisons and found no consistent differences associated
with oxycodone for treating pain intensity, adverse events, or treat-
ment acceptability. The evidence was limited by the methodologi-
cal quality and small size of the studies.
Discussion
Low-quality evidence shows that for adultswith cancerpain, oxyco-
done isnotassociatedwithbetterpain reliefor feweradverseevents
compared with other strong opioids, including morphine or oxy-
morphone.
Limitations
Theevidencequalitywas lowduetosmall samplesizes insomecases
and important study limitations in all cases, including heteroge-
neousdefinitionsofcancerpainandhigh levelsofattrition,withdata
missing frommore than 20%of the patients for pain intensity and
more than 15% of the patients for adverse events.
Comparison of FindingsWith Current Practice Guidelines
TheNational Institute for Health andCare Excellence recommends
morphineas first-lineopioid2because it is less expensive thanother
alternatives. The European Association of Palliative Care recom-
mends that any oral opioid is appropriate for first-line use.3 Our re-
view foundnodifferences inpain control betweenCRand IRoxyco-
done; however, CR opioids are generally recommended for
maintenance of pain control comparedwith IR opioids,2,5,6 and are
CLINICAL QUESTION Is oxycodone associated with greater efficacy and fewer adverse events
compared with alternative analgesics for cancer pain?
BOTTOM LINE Oxycodone was not associated with superior cancer pain relief or fewer
adverse effects compared with other strong opioids, such as morphine or oxymorphone.
However, the quality of the evidence was low.
Evidence Profile
No. of randomized clinical trials: 17 (crossover or parallel group)
Study years: Published, 1978-2014; date of last literature search,
March 3, 2014
No. of patients: 1390 (1110 analyzed for efficacy, 1170 analyzed
for safety)
Men: 47% Women: 45% (unspecified, 8%)
Race/ethnicity:Not reported
Age, mean (range): 58 years (20-91)
Setting: Inpatient and outpatient
Countries:United States, Canada, Finland, Italy, Australia,
United Kingdom, Brazil, Japan/Korea
Comparisons: Controlled-release (CR) oxycodone vs
(1) immediate-release (IR) oxycodone (4 studies); (2) CRmorphine
(6 studies); (3) CR hydromorphone (1 study); (4) extended-release
(ER) oxymorphone (1 study); (5) ER tapentadol (1 study);
intravenous (IV) oxycodone vs rectal oxycodone (1 study);
IV oxycodone followed by IR oxycodone vs IVmorphine followed
by IRmorphine (1 study); intramuscular oxycodone vs oral
oxycodone (1 study); intramuscular oxycodone vs intramuscular
morphine vs intramuscular codeine (1 study)
Primary outcome: Patient-reported pain intensity measured on
verbal or visual rating scales
Secondary outcomes: Adverse events, patient preference/
treatment acceptability, quality of life
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preferredbypatientsbecauseof theneed for fewerdaily doses and
theability toenjoyanuninterruptednight’s sleep.7Our review iscon-
sistent with these recommendations such that at a group level, cli-
niciansmay select any strong opioid for first-line treatment. For an
individual patient, one strong opioid may be tolerated better than
another, so regular assessment of pain control is needed.
Areas in Need of Future Study
Current evidence is limited by the absence of high-quality studies.
Morewell-designedandwell-powered randomizedclinical trials are
needed. Developing a single outcome that better reflects patients’
experiences of both pain and adverse events would allow a clearer
comparison.
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Figure. Pain Scores Analyzed as the StandardizedMean Difference (SMD) Between the Treatment Groups
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Favors
Oxycodone
Favors
ComparisonStudy
CR oxycodone vs IR oxycodone a
Oxycodone
Pain Score,
Mean (SD)
Total
Patients
Comparator
Pain Score,
Mean (SD)
Total
Patients
Pain Score, SMD
(95% CI)
54.21.3 (1.25) 156 1.3 (1.25) 156Kaplan, 1998 0.00 (–0.22 to 0.22)
35.41.4 (1.01) 103 1.1 (1.01) 103Parris, 1998 0.30 (0.02 to 0.57)
10.42.7 (1.9) 30 2.8 (1.9) 30Stambaugh, 2001 –0.05 (–0.56 to 0.45)
100.0Subtotal 289 289 0.10 (–0.06 to 0.26)
CR oxycodone vs CR morphine
10.124.3 (20) 23 22.9 (21) 23Bruera, 1998 0.07 (–0.51 to 0.65)
CR oxycodone vs CR hydromorphone
100.028 (22.27) 31 31 (22.27) 31Hagen, 1997 –0.13 (–0.63 to 0.37)
11.50.99 (0.62) 27 0.77 (0.36) 27Heiskanen, 1997 0.43 (–0.11 to 0.97)
8.43.15 (3) 19 2.35 (2.36) 20Mercadante, 2010 b 0.29 (-0.34 to 0.92)
34.11.3 (0.89) 79 1 (0.89) 79Mucci-LoRusso, 1998 0.34 (0.02 to 0.65)
35.92.05 (1.71) 80 2.36 (2.18) 85Riley, 2014 –0.16 (–0.46 to 0.15)
100.0Subtotal 228 234 0.14 (–0.04 to 0.32)
CR oxycodone vs ER oxymorphone
100.02.8 (1.3) 37 2.5 (1.3) 37Gabrail, 2004 0.23 (–0.23 to 0.69)
CR oxycodone vs ER tapentadol
100.02.57 (2.03) 139 2.69 (2.22) 126Imanaka, 2013 –0.06 (–0.30 to 0.18)
IR oxycodone vs IR morphine
100.01.3 (1.2) 19 1.5 (1.4) 19Kalso, 1990 –0.15 (–0.79 to 0.49)
Source: Data were adapted with permission fromWiley.1 CR indicates controlled
release; ER, extended release; IR, immediate release. SMDwas calculated using
the inverse variance fixed-effect method. The SMD can be interpreted as an
effect size, with small effect size values of 0.2; medium, 0.5; and large, 0.8.4
The size of the data markers indicates the weight of the study.
a IR oxycodone is input as the comparator group in this specific drug
comparison grouping.
bWeek 4 data.
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